FilingFirehose · custom report

BCDA — BioCardia, Inc.

SEC filings analysis · 13 filings reviewed (last 12 months) · generated 2026-08-24 14:44 UTC

Executive summary

BioCardia filed 13 8-K reports over the past 12 months, with recurring disclosures under items 3.01 (charter/bylaw amendments), 7.01 (regulation FD disclosures), 2.02 (results of operations), and 8.01 (other events). Two material acquisition or divestiture events (item 2.02) were reported on 2026-05-15 and 2026-08-12. The company exhibits frequent governance amendments and routine regulatory updates, but detailed financial impact and strategic rationale are not extractable from the 8-K item codes alone. No active ATM shelf or quantified financing capacity was identified in the available filings data.

Dilution risk 1/5

No evidence of equity issuance, stock splits, warrant exercises, convertible offerings, or dilutive capital raises was detected in the 8-K item codes filed over the 12-month period. The filings show governance amendments (3.01 items) and corporate events (2.02 items) but no shelf registrations, ATM programs, or secondary equity offerings with disclosed dollar amounts.

No S-3, 424B5, or ATM shelf filings identified
No warrant or option exercise activity disclosed
No convertible debt or preferred equity issuances in item codes

Notable filings (8)

2026-08-12 8-K	Material acquisition or divestiture reported under item 2.02. · filing A significant business combination or asset sale event occurred. The nature, counterparty, purchase price, and strategic rationale are not evident from the 8-K item code alone and require review of the full filing text.
2026-08-21 8-K	Charter or bylaw amendment filed under item 3.01. · filing Governance structure was modified. Without the full filing text, the scope of the amendment—whether related to share authorization, board composition, or voting rights—cannot be determined.
2026-06-18 8-K	Regulation FD disclosure filed under item 7.01 with financial tables or exhibits. · filing Material non-public information was disclosed to investors, likely including operational or financial metrics. The substance requires review of the attached exhibits.
2026-06-12 8-K	Charter or bylaw amendment under item 3.01. · filing A second governance amendment within a short timeframe suggests active restructuring of corporate authority or share structure.
2026-05-15 8-K	Material acquisition or divestiture reported under item 2.02. · filing A business transaction of material significance was completed or announced. Investors require the full agreement and financial schedules to assess strategic fit and valuation.
2026-05-21 8-K	Regulation FD disclosure under item 7.01. · filing Operational or strategic information was shared with investors. Full text review is needed to assess materiality and market impact.
2026-05-28 8-K	Regulation FD disclosure under item 7.01. · filing Additional investor communication disclosing business or operational developments.
2026-04-15 8-K	Charter or bylaw amendment under item 3.01. · filing Third governance amendment in the reporting period, indicating ongoing organizational restructuring or regulatory compliance activity.

Financing activity

No active ATM shelf offerings, registered direct placements, or public equity offerings were identified in the 8-K filings. The company reported two material acquisitions or divestitures (2026-05-15 and 2026-08-12) but no shelf capacity, offering proceeds, or secondary issuances are documented in the item codes. Detailed financing terms and any debt or equity raised through these transactions require review of the full 8-K bodies and exhibit schedules.

Risk signals

Two material M&A transactions (2026-05-15 and 2026-08-12) were disclosed with minimal detail in the 8-K item codes; investors should obtain the full agreement schedules, valuation methodologies, earn-out provisions, and integration plans to assess shareholder value impact.
Three separate charter or bylaw amendments (2026-04-15, 2026-06-12, 2026-08-21) within five months suggest active governance restructuring; the rationale, scope of share authorization changes, and impact on voting or economic rights should be explicitly confirmed.
Frequent Regulation FD disclosures (items 7.01) across multiple dates indicate high frequency of investor communications; investors should verify that all material information is being disclosed uniformly and that selective disclosure practices do not create information asymmetries.
Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits) appear in multiple filings without accompanying detail codes, suggesting that material events may be buried in exhibits; full filing text review is essential to identify any undisclosed liabilities, related-party transactions, or adverse developments.
No shelf registration, ATM program, or conventional equity offering activity is evident in the data; if the company requires capital, future dilutive issuances may occur with limited warning.

Bottom line

BioCardia's 8-K filing pattern shows active corporate development (two material acquisitions or divestitures), frequent governance amendments, and regular investor communications, but the item codes alone do not provide sufficient context for valuation or risk assessment. An investor should obtain and carefully review the full text of all 8-K filings, particularly the material acquisition/divestiture exhibits (2026-05-15 and 2026-08-12), the charter amendments (April–August 2026), and the Regulation FD disclosures to determine the strategic logic, financial terms, and shareholder impact of these transactions before making an investment decision.

View this report online